Publication | Open Access
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
45
Citations
33
References
2021
Year
Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyBtk Inhibitor OrelabrutinibImproved Anti-tumor EffectsImmune Checkpoint InhibitorAnti-cancer AgentB Cell LymphomaImmunotherapyOncologyRadiation Oncology
| Year | Citations | |
|---|---|---|
Page 1
Page 1